KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Asset Utilization Ratio (2011 - 2026)

Jazz Pharmaceuticals' quarterly Asset Utilization Ratio came in at 0.38 in Q1 2026, up 9.33% year-on-year from 0.35 in Q1 2025, and up 1.78% quarter-over-quarter from 0.37 in Q4 2025.

Jazz Pharmaceuticals has reported Asset Utilization Ratio for 16 years, with the latest figure at 0.38 in Q1 2026.

  • For the quarter ending Q1 2026, Asset Utilization Ratio rose 9.33% year-over-year to 0.38; the trailing twelve-month figure through Mar 2026 stood at 0.38 (up 9.33% YoY), and the FY2025 full-year result was 0.36, up 3.7% from the prior year.
  • Asset Utilization Ratio for Q1 2026 stood at 0.38, up from 0.37 in the prior quarter.
  • The five-year high for Asset Utilization Ratio was 0.38 in Q1 2026, with the low at 0.27 in Q1 2022.
  • Average Asset Utilization Ratio over 5 years is 0.34, with a median of 0.34 recorded in 2023.
  • Peak annual rise in Asset Utilization Ratio reached 49.0% in 2022, while the deepest fall reached 25.19% in 2022.
  • Tracing JAZZ's Asset Utilization Ratio over 5 years: stood at 0.34 in 2022, then decreased by 1.61% to 0.34 in 2023, then slipped by 1.18% to 0.34 in 2024, then climbed by 10.59% to 0.37 in 2025, then rose by 1.78% to 0.38 in 2026.
  • The last three Asset Utilization Ratio figures came in at 0.38 (Q1 2026), 0.37 (Q4 2025), and 0.37 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Asset Util. (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.60
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 0.47
7 Evaxion A 62.56 Bn 62.54 Bn - 0.29
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.37
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 0.85
10 Jazz Pharmaceuticals 14.35 Bn 12.51 Bn 934.80 Mn 0.38

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.38
Dec 31, 2025 0.37
Sep 30, 2025 0.37
Jun 30, 2025 0.36
Mar 31, 2025 0.35
Dec 31, 2024 0.34
Sep 30, 2024 0.34
Jun 30, 2024 0.34
Mar 31, 2024 0.34
Dec 31, 2023 0.34
Sep 30, 2023 0.34
Jun 30, 2023 0.34
Mar 31, 2023 0.34
Dec 31, 2022 0.34
Sep 30, 2022 0.33
Jun 30, 2022 0.30
Mar 31, 2022 0.27
Dec 31, 2021 0.25
Sep 30, 2021 0.22
Jun 30, 2021 0.26
Mar 31, 2021 0.37
Dec 31, 2020 0.37
Sep 30, 2020 0.37
Jun 30, 2020 0.39
Mar 31, 2020 0.41
Dec 31, 2019 0.39
Sep 30, 2019 0.37
Jun 30, 2019 0.37
Mar 31, 2019 0.37
Dec 31, 2018 0.35
Sep 30, 2018 0.34
Jun 30, 2018 0.34
Mar 31, 2018 0.32
Dec 31, 2017 0.32
Sep 30, 2017 0.32
Jun 30, 2017 0.32
Mar 31, 2017 0.32
Dec 31, 2016 0.31
Sep 30, 2016 0.34
Jun 30, 2016 0.40
Mar 31, 2016 0.39
Dec 31, 2015 0.39
Sep 30, 2015 0.38
Jun 30, 2015 0.39
Mar 31, 2015 0.38
Dec 31, 2014 0.35
Sep 30, 2014 0.33
Jun 30, 2014 0.32
Mar 31, 2014 0.34
Dec 31, 2013 0.39
Sep 30, 2013 0.38
Jun 30, 2013 0.37
Mar 31, 2013 0.34
Dec 31, 2012 0.32
Sep 30, 2012 0.28
Jun 30, 2012 0.30
Mar 31, 2012 0.56
Dec 31, 2011 1.17
Sep 30, 2011 1.35